BioAdaptives Inc
BioAdaptives, Inc. investigates, markets, and distributes natural plant, algal, and mushroom-based products and medical devices for humans and animals. It offers nutraceutical products, such as dietary supplements. The company offers Human Clinical trial; Zeranovia, a natural ingredient and uses proprietary methods of optimizing the availability of nutrients in foods and beverages; Lung Flute, a … Read more
BioAdaptives Inc (BDPT) - Total Assets
Latest total assets as of September 2025: $124.36K USD
Based on the latest financial reports, BioAdaptives Inc (BDPT) holds total assets worth $124.36K USD as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
BioAdaptives Inc - Total Assets Trend (2013–2024)
This chart illustrates how BioAdaptives Inc’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
BioAdaptives Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
BioAdaptives Inc's total assets of $124.36K consist of 100.0% current assets and 0.0% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 52.5% |
| Accounts Receivable | $2.80K | 1.1% |
| Inventory | $19.11K | 7.3% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2013–2024)
This chart illustrates how BioAdaptives Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: BioAdaptives Inc's current assets represent 100.0% of total assets in 2024, unchanged from 100.0% in 2013.
- Cash Position: Cash and equivalents constituted 52.5% of total assets in 2024, up from 16.9% in 2013.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2013.
- Asset Diversification: The largest asset category is inventory at 7.3% of total assets.
BioAdaptives Inc Competitors by Total Assets
Key competitors of BioAdaptives Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
General Mills Inc
NYSE:GIS
|
USA | $32.55 Billion |
|
Maniker F & G Co. Ltd
KQ:195500
|
Korea | ₩123.42 Billion |
|
Xiwang Foodstuffs Co Ltd
SHE:000639
|
China | CN¥6.08 Billion |
|
Nanfang Black Sesame Group Co Ltd
SHE:000716
|
China | CN¥4.57 Billion |
|
CNFC Overseas Fishery Co Ltd
SHE:000798
|
China | CN¥5.88 Billion |
|
Henan Shuanghui Investment & Development Co Ltd
SHE:000895
|
China | CN¥40.64 Billion |
|
Xinjiang Chalkis Co Ltd
SHE:000972
|
China | CN¥1.25 Billion |
|
Daehan Flour Mills Co Ltd
KO:001130
|
Korea | ₩1.61 Trillion |
BioAdaptives Inc - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - BioAdaptives Inc generates 0.05x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - BioAdaptives Inc is currently not profitable relative to its asset base.
BioAdaptives Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.07 | 0.03 | 0.01 |
| Quick Ratio | 0.04 | 0.03 | 0.00 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $-1.48 Million | $ -1.81 Million | $ -1.38 Million |
BioAdaptives Inc - Advanced Valuation Insights
This section examines the relationship between BioAdaptives Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | - |
| Latest Market Cap to Assets Ratio | 0.56 |
| Asset Growth Rate (YoY) | 151.8% |
| Total Assets | $261.88K |
| Market Capitalization | $147.23K USD |
Valuation Analysis
Below Book Valuation: The market values BioAdaptives Inc's assets below their book value (0.56 x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: BioAdaptives Inc's assets grew by 151.8% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for BioAdaptives Inc (2013–2024)
The table below shows the annual total assets of BioAdaptives Inc from 2013 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $261.88K | +151.82% |
| 2023-12-31 | $104.00K | +178.71% |
| 2022-12-31 | $37.31K | -74.89% |
| 2021-12-31 | $148.59K | +688.42% |
| 2020-12-31 | $18.85K | -22.17% |
| 2019-12-31 | $24.21K | -78.00% |
| 2018-12-31 | $110.06K | +2988.94% |
| 2017-12-31 | $3.56K | -97.57% |
| 2016-12-31 | $146.56K | +1938.34% |
| 2015-12-31 | $7.19K | -89.84% |
| 2014-12-31 | $70.76K | -41.18% |
| 2013-12-31 | $120.31K | -- |